Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Genprex, Inc.GNPX · Entity 8441 | Director · Chairman, President and CEO | February 18, 2024 | February 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Genprex, Inc.
Report date February 18, 2024 · Filed February 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,352 |
Reported balance
After 2024-02-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-02-18 · Tax withholding · Disposed 2,642 · Balance 26,352 F1: Represents shares withheld on February 18, 2024 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan. F2: This total represents the number of shares of Common Stock directly beneficially owned following this reported transaction and the 1-for-40 reverse stock split of the Company's Common Stock effected as of February 2, 2024 (the "RSS"). |
| Common StockSEC Table I · non-derivative | Indirectby Alizzita Ltd | 520 |
Reported balance
Holding disclosure · report date 2024-02-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 520 F3: This total represents the number of shares of Common Stock indirectly beneficially owned following the RSS. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld on February 18, 2024 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan.
F2: This total represents the number of shares of Common Stock directly beneficially owned following this reported transaction and the 1-for-40 reverse stock split of the Company's Common Stock effected as of February 2, 2024 (the "RSS").
F3: This total represents the number of shares of Common Stock indirectly beneficially owned following the RSS.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2024 Filed Feb 21, 2024 21:32 UTC | Genprex, Inc. GNPX · Entity 8441 | Tax withholdingCommon Stock | 2,642 | $4.40 | $11,624.80 |
DisclosureSEC source: 0001437749-24-005058 · rdgdoc.xml · nonDerivative · entry 1 Varner John Rodney · CIK 0001735543 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,352 F1 · shares: Represents shares withheld on February 18, 2024 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan. F2 · balance_after: This total represents the number of shares of Common Stock directly beneficially owned following this reported transaction and the 1-for-40 reverse stock split of the Company's Common Stock effected as of February 2, 2024 (the "RSS"). Read SEC document |
| April 21, 2023 Filed Apr 24, 2023 13:03 UTC | Genprex, Inc. GNPX · Entity 8441 | PurchaseCommon Stock | 19,000 | $1.06 | $20,045.00 |
DisclosureSEC source: 0001437749-23-010871 · rdgdoc.xml · nonDerivative · entry 1 Varner John Rodney · CIK 0001735543 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · by Alizzita Ltd Disclosed balance after: 20,800 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.0299 to $1.07 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 18, 2023 Filed Feb 22, 2023 23:21 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantCommon Stock | 625,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-004235 · rdgdoc.xml · nonDerivative · entry 1 Varner John Rodney · CIK 0001735543 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,159,735 F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests in installments of 50% on the first anniversary of the date of grant and the remaining 50% on the second anniversary of the date of grant. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value ("Common Stock") on a one-to-one basis. F2 · balance_after: This total now excludes 10,000 shares of Common Stock that were previously reported as being purchased on March 29, 2018 and directly held by Reporting Person. The prior inclusion of these shares was inadvertent and due to an administrative error. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:35 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantStock Option (right to buy) · Derivative | 1,062,250 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001437749-22-002746 · rdgdoc.xml · derivative · entry 1 Varner John Rodney · CIK 0001735543 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062,250 Underlying: Common Stock · 1,062,250 shares Expires 2032-02-04 F1 · derivative.exercise_date: The option (the "Option") was granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (the "Plan"). The Option shall vest and become exercisable as to one third (1/3) of the total number of shares (the "Shares") of the Company's common stock, $.001 par value subject to the Option on February 4, 2023 (the "Vesting Commencement Date") and thereafter shall vest and become exercisable as to an additional 1/24 of the remaining Shares subject to the Option on each monthly anniversary of the Vesting Commencement Date until fully vested and exercisable, in each case provided that the Optionee continues to serve as a Service Provider (as defined in the Plan) through the applicable vesting date. Read SEC document |
| June 14, 2021 Filed Feb 14, 2022 21:48 UTC | Genprex, Inc. GNPX · Entity 8441 | GiftCommon Stock | 1,614,152 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-003281 · rdgdoc.xml · nonDerivative · entry 1 Varner John Rodney · CIK 0001735543 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by Laura Lane Biosciences, LLC Disclosed balance after: 0 F1 · acquired: On June 14, 2021, Mr. Varner resigned as the manager of Laura Lane Biosciences, LLC, and Mr. Varner and his spouse resigned as trustees of the trusts that comprise all of the members of Laura Lane Biosciences, LLC. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 20:46 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantStock Option (right to buy) · Derivative | 460,000 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001437749-21-006913 · rdgdoc.xml · derivative · entry 1 Varner John Rodney · CIK 0001735543 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,000 Underlying: Common Stock · 460,000 shares Expires 2031-03-19 F1 · derivative.exercise_date: One third (1/3) of the Shares subject to the Option shall vest on each annual anniversary of March 19, 2021 so that one hundred percent (100%) of the shares subject to the Option are vested on the third anniversary of March 19, 2021 provided that the optionee continues to serve as a Service Provider (as defined in Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 21:54 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantStock Option (right to buy) · Derivative | 530,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001437749-20-018692 · rdgdoc.xml · derivative · entry 1 Varner John Rodney · CIK 0001735543 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530,000 Underlying: Common Stock · 530,000 shares Expires 2030-08-20 F1 · derivative.exercise_date: One thirty-sixth (1/36) of the Shares subject to the Option shall vest on each monthly anniversary of August 21, 2020 so that one hundred percent (100%) of the shares subject to the Option are vested on the third anniversary of August 21, 2020, provided that the optionee continues to serve as a Service Provider (as defined in Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 17:11 UTC | Genprex, Inc. GNPX · Entity 8441 | PurchaseCommon Stock | 1,800 | $0.89 | $1,594.62 |
DisclosureSEC source: 0001437749-19-018060 · rdgdoc.xml · nonDerivative · entry 1 Varner John Rodney · CIK 0001735543 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · by Alizzita Ltd. Disclosed balance after: 1,800 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8856 per share to $0.8880 per share. A total of 100 shares were purchased at $0.8856 per share, a total of 1,500 shares were purchased at $0.8858 per shares, a total of 100 shares were purchased at $0.8859 per share, and a total of 100 shares were purchased at $0.8880 per share. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 19:45 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantStock Option (Right to Buy) · Derivative | 615,384 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001209191-19-005728 · doc4.xml · derivative · entry 1 Varner John Rodney · CIK 0001735543 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,384 Underlying: Common Stock · 615,384 shares Expires 2029-01-25 F1 · derivative.exercise_date: One thirty-sixth (1/36) of the Shares subject to the Option shall vest on each monthly anniversary of January 25, 2019 so that one hundred percent (100%) of the shares subject to the Option are vested on the third anniversary of January 25, 2019. Read SEC document |
| November 02, 2018 Filed Feb 5, 2019 16:07 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantStock Option (Right to Buy) · Derivative | 551,284 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001209191-19-007170 · doc4.xml · derivative · entry 1 Varner John Rodney · CIK 0001735543 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 551,284 Underlying: Common Stock · 551,284 shares Expires 2028-11-02 F1 · derivative.exercise_date: One hundred percent (100%) of the Shares subject to the Option shall vest upon the date of grant of the Option. Read SEC document |
| March 29, 2018 Filed Apr 5, 2018 20:57 UTC | Genprex, Inc. GNPX · Entity 8441 | PurchaseCommon Stock | 10,000 | $5.00 | $50,000.00 |
DisclosureSEC source: 0001185185-18-000642 · form4-varner040518.xml · nonDerivative · entry 1 Varner John Rodney · CIK 0001735543 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,735 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.